NCT04804319

Brief Summary

The aim of this study is to explore the interplay between environmental (abiotic) factors in the gut and the gut microbiota composition, diversity and metabolism. Such insights could help us understand personal responses to diets and be a first step towards personalized dietary recommendations targeting the gut microbiome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
63

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 4, 2021

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 18, 2021

Completed
26 days until next milestone

Study Start

First participant enrolled

April 13, 2021

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 29, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 29, 2021

Completed
Last Updated

December 6, 2024

Status Verified

December 1, 2024

Enrollment Period

8 months

First QC Date

March 4, 2021

Last Update Submit

December 3, 2024

Conditions

Keywords

MicrobiomeMetabolomicsNutrition

Outcome Measures

Primary Outcomes (1)

  • Faecal pH vs gut microbial saccharolytic/proteolytic metabolism

    We test whether faecal pH is positively associated with microbial-derived proteolytic metabolites (i.e. p-cresol sulfate and phenylacetylglutamine) in urine and negatively associated with microbial-derived saccharolytic metabolites in faeces (i.e. acetate, butyrate and propionate)

    Day 1-9

Secondary Outcomes (6)

  • Abiotic factors vs faecal metagenomic profile

    Day 1-9

  • Abiotic factors vs faecal metabolome

    Day 1-9

  • Abiotic factors vs urine metabolome

    Day 1-9

  • Abiotic factors vs blood metabolome

    Day 2 and 9

  • Abiotic factors vs microbial-derived metabolites

    Day 1-9

  • +1 more secondary outcomes

Other Outcomes (34)

  • Faecal microbiome

    Day 1-9

  • Faecal metabolome

    Day 1-9

  • In vitro metabolic profiling

    Day 1-9

  • +31 more other outcomes

Interventions

9-days study with habitual diet including one standardized breakfast on a single day

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Healthy volunteers

You may qualify if:

  • kg/m2 BMI
  • Willing to daily collect a urine and stool sample at home and able to store them in their own freezer in a provided containers throughout the 9-days trial
  • Willing to eat sweet corn and report corn-intestinal transit time questionnaire
  • Willing to record 9 days dietary intake and defecation pattern
  • Willing to have blood samples drawn two times
  • Owns a device with access to the internet and is willing to use myfood24 platform
  • Known ability to tolerate paracetamol and willing to consume ½ paracetamol tablet dissolved in water (250mg)
  • Willing to eat rye bread, butter, jam, egg, yoghurt, berries and nuts

You may not qualify if:

  • Any condition that makes the project responsible researcher to doubt the feasibility of the volunteer´s participation
  • Pregnant or lactating women
  • Suffering from inflammatory bowel syndrome (IBS), small intestinal bacterial overgrowth (SIBO) or inflammatory bowel diseases (IBD)
  • Intake of antibiotics, diarrhea inhibitors and laxatives ˂ 1month
  • Current chronic or infectious diseases
  • Diagnosis of diabetes
  • History of cancer within the past 5 years (except adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer)
  • Frequent intake of painkillers or other medication (mild antidepressants and contraceptive pills are allowed)
  • Concurrent participation in another trial
  • Intake of medications potentially altering gastric pH (proton pump inhibitors, histamine receptor antagonists, antacids)
  • Intake of medications potentially altering the gastrointestinal motility (prokinetics, antiemetic agents, anticholinergic agents, narcotic analgetics, nonsteroidal anti-inflammatory drugs)
  • Dysphagia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Copenhagen, Department of Nutrition, Exercise and Sports

Copenhagen, 1958, Denmark

Location

Related Publications (1)

  • Prochazkova N, Laursen MF, La Barbera G, Tsekitsidi E, Jorgensen MS, Rasmussen MA, Raes J, Licht TR, Dragsted LO, Roager HM. Gut physiology and environment explain variations in human gut microbiome composition and metabolism. Nat Microbiol. 2024 Dec;9(12):3210-3225. doi: 10.1038/s41564-024-01856-x. Epub 2024 Nov 27.

MeSH Terms

Conditions

Metabolic Diseases

Condition Hierarchy (Ancestors)

Nutritional and Metabolic Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

March 4, 2021

First Posted

March 18, 2021

Study Start

April 13, 2021

Primary Completion

November 29, 2021

Study Completion

November 29, 2021

Last Updated

December 6, 2024

Record last verified: 2024-12

Locations